Bacteremia due to Methicillin-Resistant Staphylococcus aureus

• Autores: Marisa Holubar, Lina Meng, Stan Deresinski
• Localización: Infectious disease clinics of North America, ISSN 0891-5520, Vol. 30, Nº. 2, 2016 (Ejemplar dedicado a: Antibiotic Resistance: Challenges and Opportunities), págs. 491-507
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • This article reviews recent clinical evidence for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Vancomycin remains the initial antibiotic of choice for the treatment of patients with MRSA bacteremia and endocarditis due to isolates with vancomycin minimum inhibitory concentration ≤2 μg/mL, whereas daptomycin is an effective alternative, and ceftaroline seems promising. Treatment options for persistent MRSA bacteremia or bacteremia due to vancomycin-intermediate or vancomycin-resistant strains include daptomycin, ceftaroline, and combination therapies. There is a critical need for high-level evidence from clinical trials to allow optimally informed decisions in the treatment of MRSA bacteremia and endocarditis.